Monopar Therapeutics Stock Statistic Functions Beta
| MNPR Stock | USD 57.00 -1.51 -2.58% |
| Symbol |
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Monopar Therapeutics correlated with the market. If Beta is less than 0 Monopar Therapeutics generally moves in the opposite direction as compared to the market. If Monopar Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Monopar Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Monopar Therapeutics is generally in the same direction as the market. If Beta > 1 Monopar Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Monopar Therapeutics Technical Analysis Modules
Most technical analysis of Monopar Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Monopar from various momentum indicators to cycle indicators. When you analyze Monopar charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. A high-level view of Monopar Therapeutics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 2.76. Monopar Therapeutics has a market cap of 380.91 M, ROE of -26.54%. 
Ellen Johnson ยท Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Monopar Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Monopar (USA Stocks:MNPR) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Monopar Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Monopar Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Monopar Stock is Curated By:
Ellen Johnson ยท Member of Macroaxis Editorial BoardBecome your own money manager
Tracking Monopar Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested over 20 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | FinTech Invested over 60 shares | |
 | Impulse Invested over 200 shares | |
 | Momentum Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Advertising Invested few shares | |
 | Disruptive Technologies Invested few shares | |
 | Power Assets Invested over 200 shares |
Additional Tools for Monopar Stock Analysis
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |